Kelun-Biotech Unveils Future Strategy and Achievements at 44th J.P. Morgan Healthcare Conference

Kelun-Biotech's Remarkable Showcase at JPM Healthcare Conference

From January 12 to 15, 2026, the prestigious J.P. Morgan Healthcare Conference (JPMHC) took place in San Francisco, California. This annual event is known for gathering healthcare leaders to discuss innovations and advancements in the industry. Among the noteworthy participants was Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., who delivered a significant keynote presentation on January 15, highlighting the company’s recent achievements and outlining their strategic vision for the future.

Founded in 2012, Kelun-Biotech has swiftly established itself as a pioneer in the innovative drug sector in China. The company stands out for its advanced research and development (R&D) capabilities, bolstered by the proprietary OptiDC™ platform designed for antibody-drug conjugates (ADCs) and novel drug conjugates (DCs). This platform underpins the company’s portfolio aimed at effectively treating various cancer types. Currently, Kelun-Biotech has two ADC products on the market: sacituzumab tirumotecan (sac-TMT, branded as 佳泰莱®) for breast cancer, and trastuzumab botidotin (舒泰莱®) for lung cancer.

In addition to these marketed products, the company has an ambitious pipeline with nine promising ADC and novel DC drugs undergoing clinical trials, including advancements in bispecific ADCs and radiopharmaceutical conjugates (RDCs). The firm is actively conducting nine pivotal studies targeting high-incidence tumor types in China, including breast cancer and gastrointestinal tumors, along with several Phase II clinical trials aimed at gynecological cancers. Diversification is also a key focus for the company, which is expanding its approaches into non-oncology disease areas.

Kelun-Biotech's commitment to research excellence has yielded a substantial number of publications and presentations at leading international conferences. Notably, the findings from Kelun-Biotech's studies have been showcased at prestigious gatherings, with three research results selected for oral presentations at the American Society of Clinical Oncology (ASCO) annual meeting and additional accolades at the European Society for Medical Oncology (ESMO) Congress.

In terms of commercialization, Kelun-Biotech has crafted a competitive portfolio, led by sac-TMT, which has received regulatory approval in China for three distinct indications. The company has also secured approval for trastuzumab botidotin for the treatment of HER2-positive breast cancer, marking a significant milestone as the first domestically developed HER2-directed ADC approved in this category. Moreover, other innovative products like the anti-EGFR monoclonal antibody Cetuximab N01 (达泰莱®) for colorectal cancer, and the anti-PD-L1 monoclonal antibody tagitanlimab (科泰莱®) for nasopharyngeal carcinoma have been launched successfully. Anticipation is high for the A400 small-molecule RET inhibitor, which is projected to gain approval, pushing the number of commercially available products in China to five.

Kelun-Biotech is not only making strides in the domestic market but is also enhancing its presence on the global stage by forging strategic partnerships for maximizing its pipeline's potential. Collaborations with prominent global players like MSD, Ellipses, and Windward Bio are geared toward advancing various clinical programs, including globally coordinated Phase III trials.

The significant progress in clinical development and commercialization is attributed to the company's dedication to innovative R&D. Kelun-Biotech relies on its OptiDC™ platform, which allows for the tailored design of drug candidates that optimize safety and effectiveness. By pursuing a multi-faceted innovation strategy, the company is broadening its scope of research to include novel targets, diverse drug payloads, and conjugation technologies across both oncology and non-oncology applications.

Looking to the future, Kelun-Biotech is committed to reinforcing its foundations in R&D, operational capabilities, and technology enhancement with five key development strategies. Central to these efforts is enhancing its global operations—improving product development pathways, regulatory registration, and market commercialization strategies beyond China—to realize its ambition of becoming a world-class biopharmaceutical entity.

For further insights and presentation materials from the keynote speech, be sure to visit the Investor Relations page on Kelun-Biotech's official website.

About Kelun-Biotech

Kelun-Biotech (6990.HK), a subsidiary of Kelun Pharmaceutical (002422.SZ), focuses on the development, manufacturing, and global commercialization of cutting-edge biological drugs and small molecule treatments. With a targeted approach to major diseases, including solid tumors and autoimmune disorders, Kelun-Biotech is dedicated to creating a comprehensive, globally-oriented drug development platform aimed at meeting critical healthcare needs. The company currently oversees over 30 innovative drug projects, with numerous assets in clinical stages of development. For additional information, please visit Kelun-Biotech's website.